-
Medicinal Use of Different Cannabis Strains: Results from a Large Prospective Survey in Germany Pharmacopsychiatry (IF 4.3) Pub Date : 2024-03-12 Natalia Szejko, Eva Becher, Florian Heimann, Franjo Grotenhermen, Kirsten R. Müller-Vahl
Background Up to now, it is unclear whether different medicinal cannabis (MC) strains are differently efficacious across different medical conditions. In this study, the effectiveness of different MC strains was compared depending on the disease to be treated. Methods This was an online survey conducted in Germany between June 2020 and August 2020. Patients were allowed to participate only if they
-
Risperidone-Induced Leukoneutropenia: Evidence from a Positive Rechallenge and Review of the Literature Pharmacopsychiatry (IF 4.3) Pub Date : 2024-03-12 Dhouha Sahnoun, Ahlem Ghanmi, Soumaya Gazzeh, Bochra Saguem, Raoudha Slim, Jaafar Nakhli, Chaker Ben Salem
Antipsychotics can cause hematologic disorders, and they can have life-threatening consequences. Risperidone, less commonly associated with hematologic adverse effects, is an atypical antipsychotic medication used to treat conditions such as schizophrenia, bipolar disorder and irritability associated with autism. While risperidone primarily affects the central nervous system, it can have some hematologic
-
Implications of Online Self-Diagnosis in Psychiatry Pharmacopsychiatry (IF 4.3) Pub Date : 2024-03-12 Scott Monteith, Tasha Glenn, John R. Geddes, Peter C. Whybrow, Eric D. Achtyes, Michael Bauer
Online self-diagnosis of psychiatric disorders by the general public is increasing. The reasons for the increase include the expansion of Internet technologies and the use of social media, the rapid growth of direct-to-consumer e-commerce in healthcare, and the increased emphasis on patient involvement in decision making. The publicity given to artificial intelligence (AI) has also contributed to the
-
Perceptions, Experiences, and Patterns of Cannabis Use in Individuals with Mood and Anxiety Disorders in the Context of Cannabis Legalization and Medical Cannabis Program in Canada – A Qualitative Study Pharmacopsychiatry (IF 4.3) Pub Date : 2024-03-11 Ankita Das, Christian S. Hendershot, M.Ishrat Husain, Yuliya Knyahnytska, Sonja Elsaid, Bernard Le Foll, Stefan Kloiber
Introduction Perceptions of cannabis as a potential medical treatment for mood and anxiety disorders have been increasing in the context of legalizations, availability, and medical cannabis programs, though current evidence predominately indicates risks and negative effects of cannabis use (CU) on mental health outcomes. This study aims to understand motivations, perceptions, effects, and patterns
-
Cannabinoids for Behavioral Symptoms in Dementia: An Overview Pharmacopsychiatry (IF 4.3) Pub Date : 2024-03-06 Barbara Broers, Federica Bianchi
Dementia, with loss of memory, cognitive abilities, and independent daily functioning, is increasing worldwide, related to an aging population. Currently, there is no curative treatment for dementia. Treatment of the frequently occurring behavioral and psychological symptoms of dementia (BPSD) is partially effective and associated with significant side effects. Cannabinoids are lipophilic molecules
-
Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature Pharmacopsychiatry (IF 4.3) Pub Date : 2024-03-01 Kirsten R. Müller-Vahl
Although an increasing number of patients suffering from mental illnesses self-medicate with cannabis, current knowledge about the efficacy and safety of cannabis-based medicine in psychiatry is still extremely limited. So far, no cannabis-based finished product has been approved for the treatment of a mental illness. There is increasing evidence that cannabinoids may improve symptoms in autism spectrum
-
Unraveling the Influence of Age, IQ, Education, and Negative Symptoms on Neurocognitive Performance in Schizophrenia: A Conditional Inference Tree Analysis Pharmacopsychiatry (IF 4.3) Pub Date : 2024-02-22 Xenia M. Hart, Yasue Mitsukura, Robert R. Bies, Hiroyuki Uchida
Introduction The complex nature of neurocognitive impairment in schizophrenia has been discussed in light of the mixed effects of antipsychotic drugs, psychotic symptoms, dopamine D2 receptor blockade, and intelligence quotient (IQ). These factors have not been thoroughly examined before. Methods This study conducted a comprehensive re-analysis of the CATIE data using machine learning techniques, in
-
The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics Pharmacopsychiatry (IF 4.3) Pub Date : 2024-02-14 Maike Scherf-Clavel, Heike Weber, Stefan Unterecker, Amelie Frantz, Andreas Eckert, Andreas Reif, Jürgen Deckert, Martina Hahn
Introduction CYP2D6 and CYP2C19 functional status as defined by genotype is modulated by phenoconversion (PC) due to pharmacokinetic interactions. As of today, there is no data on the effect size of PC for CYP2C19 functional status. The primary aim of this study was to investigate the impact of PC on CYP2C19 functional status. Methods Two patient cohorts (total n=316; 44.2±15.4 years) were investigated
-
Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review Pharmacopsychiatry (IF 4.3) Pub Date : 2024-01-24
The endocannabinoid system shows promise as a novel target for treating psychiatric conditions. Cannabidiol (CBD), a naturally occurring cannabinoid, has been investigated in several psychiatric conditions, with diverse effects and an excellent safety profile compared to standard treatments. Even though the body of evidence from randomised clinical trials is growing, it remains relatively limited in
-
Effectiveness of Medical Cannabis for the Treatment of Depression: A Naturalistic Outpatient Study Pharmacopsychiatry (IF 4.3) Pub Date : 2024-01-11 Michael Specka, Udo Bonnet, Lisa Schmidberg, Julian Wichmann, Martin Keller, Christian Scholze, Norbert Scherbaum
Background There is a lack of studies on the course and effectiveness of medical cannabis in the treatment of major depressive disorder (MDD). Methods Retrospective longitudinal (18 weeks) study of n=59 outpatients with MDD, treated with medical cannabis via a telemedical platform. Previous treatment with antidepressant medication was required for inclusion into the study. Standardized data collection
-
Overview: Chronic Pain and Cannabis-Based Medicines Pharmacopsychiatry (IF 4.3) Pub Date : 2024-01-10
Chronic pain is primarily conceptualized as a disease in its own right when it is associated with emotional distress and functional impairment. Pathophysiologically, dysfunction of the cortico-mesolimbic connectome is of major importance, with overlapping signals in the nociceptive and stress systems. The endocannabinoid system plays an important role in the central processing of nociceptive signals
-
Patient Perspectives on Pharmacotherapy of Alcohol Dependence Pharmacopsychiatry (IF 4.3) Pub Date : 2023-12-05 Julian Wellensiek, Michael Specka, Johannes Just, Markus Banger, Udo Bonnet, Norbert Scherbaum
Introduction Pharmacotherapy with drugs like naltrexone or acamprosate is a well-evaluated element in the treatment of alcohol dependence (AD). However, in many countries, these medications are rarely administered. The objective of the present study was to identify from patients’ perspective factors that prevent the initiation and compliance with pharmacological treatment of AD. Methods Patients from
-
Augmentation of Electroconvulsive Therapy with Oral Caffeine: A Retrospective Analysis of 40 Patients with Major Depression Pharmacopsychiatry (IF 4.3) Pub Date : 2023-11-23 Peter Nyhuis, Dorothea Mücke, Michael Specka, Norbert Scherbaum
Objective Studies have demonstrated the efficacy of injectable caffeine as an augmentation method in electroconvulsive therapy (ECT). This study investigated whether orally administered caffeine increases seizure duration during ECT. Methods Medical records of 40 patients treated with a series of ECT were retrospectively analyzed. Patients whose electroencephalogram (EEG) seizure duration had dropped<30 s
-
The Effect of Electroconvulsive Therapy on Specific Catatonia Symptoms and Predictors of Late Response Pharmacopsychiatry (IF 4.3) Pub Date : 2023-11-23 Sigrid Breit, Agnes Meyer, Wolfgang Schmitt, Tobias Bracht, Sebastian Walther
Introduction Electroconvulsive therapy (ECT) is known to be effective in the treatment of catatonia, reaching response rates of about 80 to 100%. It is indicated in cases of treatment resistance to benzodiazepines and in life-threatening conditions such as malignant catatonia. Beneficial effects on specific symptoms or predictors of response are less clear. The objective of this retrospective study
-
Prevalence of COVID-19 and Psychotropic Drug Treatment in Psychiatric In-patients in Germany in 2020: Results from a Nationwide Pilot Survey Pharmacopsychiatry (IF 4.3) Pub Date : 2023-11-09
Introduction In patients with a pre-existing mental disorder, an increased risk for a first manifestation of a psychiatric disorder in COVID-19 patients, a more severe course of COVID-19 and an increased mortality have been described. Conversely, observations of lower COVID-19 incidences in psychiatric in-patients suggested protective effects of psychiatric treatment and/or psychotropic drugs against
-
Clozapine-Induced Stuttering: Case Report and Literature Review. Pharmacopsychiatry (IF 4.3) Pub Date : 2023-11-09 Fares Jaballah,Amina Aissa,Uta Ouali,Yosra Zgueb,Rabaa Jomli
-
Medical Cannabis Legalization: No Contribution to Rising Stimulant Rates in the USA Pharmacopsychiatry (IF 4.3) Pub Date : 2023-10-26
Introduction There has been a pronounced increase in the use of Schedule II stimulants to treat attention-deficit hyperactivity disorder (ADHD) in the United States over the last two decades. Interestingly, chronic medical cannabis (MC) use can present with cognitive impairments that resemble ADHD symptoms. This study aimed to determine if MC legalization increased prescription stimulant distribution
-
Factors Associated with Antidepressant Effects of Ketamine: A Reanalysis of Double-Blind Randomized Placebo-Controlled Trial of Intravenous Ketamine for Treatment-Resistant Depression Pharmacopsychiatry (IF 4.3) Pub Date : 2023-10-16 Kengo Yonezawa, Hiroyuki Uchida, Taisuke Yatomi, Yohei Ohtani, Kie Nomoto-Takahashi, Shinichiro Nakajima, Masaru Mimura, Hideaki Tani
Introduction Predictors of treatment response to intravenous ketamine remain unclear in patients with treatment-resistant depression (TRD); therefore, this study aimed to clarify these predictors using the US National Institutes of Health database of clinical trials. Methods Data from a placebo-controlled, double-blind, randomized controlled trial were used to assess the efficacy of intravenous ketamine
-
Association of Four Medication Classes and Non-suicidal Self-injury in Adolescents with Affective Disorders – A Retrospective Chart Review Pharmacopsychiatry (IF 4.3) Pub Date : 2023-09-18 Vincent Eggart, Matin Mortazavi, Sophie-Kathrin Kirchner, Daniel Keeser, Lisa Brandstetter, Alkomiet Hasan, Elias Wagner
Background Non-suicidal self-injury (NSSI) behaviour is frequently observed in children and adolescents with psychiatric conditions. Affected individuals are regularly treated with psychotropic drugs, although the impact of these agents on NSSI behaviour remains elusive. Methods We performed a retrospective chart review from clinical routine data in a large cohort (N=1140) of adolescent inpatients
-
Interpersonal Needs, Mental Pain, and Hopelessness in Psychiatric Inpatients with Suicidal Ideation Pharmacopsychiatry (IF 4.3) Pub Date : 2023-09-12 Isabella Berardelli, Elena Rogante, Salvatore Sarubbi, Maria Anna Trocchia, Ludovica Longhini, Denise Erbuto, Marco Innamorati, Maurizio Pompili
Introduction Suicide is a leading cause of death worldwide and models may help the understanding of the phenomenon and ultimately reduce its burden through effective suicide prevention strategies. The Interpersonal Theory of Suicide and Shneidman’s Model have tried to describe different unmet needs related to suicidal ideation. The study aims to assess the association between thwarted belongingness
-
Longitudinal Digital Mood Charting in Bipolar Disorder: Experiences with ChronoRecord Over 20 Years Pharmacopsychiatry (IF 4.3) Pub Date : 2023-09-07 Michael Bauer, Tasha Glenn, Martin Alda, Paul Grof, Rita Bauer, Ulrich W. Ebner-Priemer, Stefan Ehrlich, Andrea Pfennig, Maximilian Pilhatsch, Natalie Rasgon, Peter C. Whybrow
Introduction Longitudinal study is an essential methodology for understanding disease trajectories, treatment effects, symptom changes, and long-term outcomes of affective disorders. Daily self-charting of mood and other illness-related variables is a commonly recommended intervention. With the widespread acceptance of home computers in the early 2000s, automated tools were developed for patient mood
-
Challenges and Ethical Considerations to Successfully Implement Artificial Intelligence in Clinical Medicine and Neuroscience: a Narrative Review Pharmacopsychiatry (IF 4.3) Pub Date : 2023-08-29 Scott Monteith, Tasha Glenn, John R. Geddes, Eric D. Achtyes, Peter C. Whybrow, Michael Bauer
This narrative review discusses how the safe and effective use of clinical artificial intelligence (AI) prediction tools requires recognition of the importance of human intelligence. Human intelligence, creativity, situational awareness, and professional knowledge, are required for successful implementation. The implementation of clinical AI prediction tools may change the workflow in medical practice
-
Does Lidocaine Shorten Seizure Duration in Electroconvulsive Therapy? Pharmacopsychiatry (IF 4.3) Pub Date : 2023-08-29 Jose López-Ilundain, Alejandro Ballesteros Prados, Ángela S. Rosero Enriquez, Mónica Enguita-Germán, Estefania Uriarte Rosquil, Jose López Gil, Ana Marmol Fábrega, Estitxu Martinez de Zabarte Moraza, Alex R. Maughan, Javier Yoldi-Murillo
Background Electroconvulsive therapy (ECT) is an effective short-term treatment for schizophrenia and depression, amongst other disorders. Lidocaine is typically added to reduce pain from intravenous propofol injection. However, depending on the dose used in the ECT setting, it can shorten seizure duration. The aim of this study was to investigate the effect of lidocaine dose on seizure duration. Methods
-
Valproic Acid Induced Thrombocytopenia in an Elderly Man with Schizoaffective Disorder: A Case Report. Pharmacopsychiatry (IF 4.3) Pub Date : 2023-08-21 Yun Tien
-
Effects of Early Clozapine Treatment on Remission Rates in Acute Schizophrenia (The EARLY Trial): Protocol of a Randomized-Controlled Multicentric Trial Pharmacopsychiatry (IF 4.3) Pub Date : 2023-07-28 Elias Wagner, Wolfgang Strube, Thomas Görlitz, Aslihan Aksar, Ingrid Bauer, Mattia Campana, Joanna Moussiopoulou, Alexander Hapfelmeier, Petra Wagner, Silvia Egert-Schwender, Robert Bittner, Kathrin Eckstein, Igor Nenadić, Tilo Kircher, Berthold Langguth, Eva Meisenzahl, Martin Lambert, Sigrid Neff, Berend Malchow, Peter Falkai, Dusan Hirjak, Kent-Tjorben Böttcher, Andreas Meyer-Lindenberg, Christiane
Background Quick symptomatic remission after the onset of psychotic symptoms is critical in schizophrenia treatment, determining the subsequent disease course and recovery. In this context, only every second patient with acute schizophrenia achieves symptomatic remission within three months of initiating antipsychotic treatment. The potential indication extension of clozapine—the most effective antipsychotic—to
-
Lithium Therapy in Old Age: Recommendations from a Delphi Survey Pharmacopsychiatry (IF 4.3) Pub Date : 2023-07-28 Julia Christl, Bruno Müller-Oerlinghausen, Michael Bauer, Daniel Kamp, Fabian Fußer, Jens Benninghoff, Rosa A. Fehrenbach, Christian Lange-Asschenfeldt, Michael Rapp, Bernd Ibach, Rainer Schaub, Axel Wollmer, Timm Strotmann-Tack, Michael Hüll, Susanne Biermann, Katharina Roscher, Bernd Meissnest, Alexander Menges, Bernd Weigel, Dorothee Maliszewski-Makowka, Christian Mauerer, Martin Schaefer, Beate
Introduction While lithium (Li) has been well established for the treatment of bipolar disorder, geriatric patients require special attention when it comes to issues of drug safety. Declining renal function, amongst other medical conditions, and polypharmacy may pose increased risks. Only a few previous studies have addressed the management of Li in geriatric patients. Methods Twenty-four German medical
-
Revisiting the World’s Strictest COVID-19 Lockdown: Formidable Mental Health Challenges Pharmacopsychiatry (IF 4.3) Pub Date : 2023-07-12 Beier Guan, Ruihua Li, Chuanning Huang, Jiang Du, Min Zhao, Shuyan Liu
Introduction Many nations have implemented lockdowns to prevent and minimize the spread of infections in healthcare settings. However, the impact of lockdown duration on mental health remains controversial. Methods We conducted a retrospective study using online questionnaires to assess the mental health status of the general population during the Shanghai lockdown period from March to May 2022. The
-
High Prescribing and State-Level Variation in Z-Drug Use Among Medicare Patients Pharmacopsychiatry (IF 4.3) Pub Date : 2023-06-07 Kaitlin E. Anderson, Rachel I. Gifeisman, James L. Basting, Donovan J. Harris, Antonica R. Rajan, Kenneth L. McCall, Brian J. Piper
Background Z-drugs are nonbenzodiazepine hypnotics used for sleep initiation and maintenance; these drugs increase the risk of fall-related injuries in older adults. The American Geriatrics Society’s Beers criteria classifies Z-drugs as high-risk and strongly recommends avoiding prescribing Z-drugs to older adults due to adverse effects. The study objectives were to determine the prevalence of Z-drug
-
Establishing Core Symptoms of Acute Serotonin Reuptake Inhibitor Withdrawal: Results from an International Survey of Online Peer-Support Communities Pharmacopsychiatry (IF 4.3) Pub Date : 2023-05-30 Bryan Shapiro, Eric Kramer, Dina Khoury, Adrian Preda
Background Serotonin reuptake inhibitor (SRI) antidepressants are commonly associated with withdrawal reactions. The Discontinuation Emergent Signs and Symptoms (DESS) checklist has been considered the gold standard research and screening tool for SRI withdrawal but has several limitations, including its length, lack of specificity, and omission of baseline symptom and symptom severity scores, making
-
GABAergic Effects of Etifoxine and Alprazolam Assessed by Double Pulse TMS Pharmacopsychiatry (IF 4.3) Pub Date : 2023-05-23 Marco Riebel, Benedikt von Pappenheim, Carolina Kanig, Caroline Nothdurfter, Thomas C. Wetter, Rainer Rupprecht, Jens Schwarzbach
Introduction There is a need for novel anxiolytics with improved side effect profiles compared to benzodiazepines. A promising candidate with alternative pharmacodynamics is the translocator protein ligand, etifoxine. Methods To get further insight into its mechanisms of action and side effects compared to the benzodiazepine alprazolam, we performed a double-blind, placebo-controlled, repeated-measures
-
„AGNP-Preis für Forschung in der Psychopharmakologie“ in Höhe von 5.000 € Pharmacopsychiatry (IF 4.3) Pub Date : 2023-05-15
Wohl kaum eine andere Arzneimittelgruppe hat durch ihre Einführung so immense therapeutische Möglichkeiten eröffnet wie die Psychopharmaka. In den über 60 Jahren seit ihrer Entdeckung haben sie vielen psychisch Kranken entscheidend geholfen. Heute sind sie aus der Therapie psychischer Erkrankungen nicht mehr wegzudenken.
-
The Role of Circadian Rhythmicity and CLOCK Genes in Psychiatry Pharmacopsychiatry (IF 4.3) Pub Date : 2023-05-15 Denise Palm, Johannes Thome
Circadian rhythms are biological oscillations, that perpetuate themselves even in the absence of “zeitgebers” (external time cues), with a period of approximately 24 hours. The master pacemaker is the suprachiasmatic nucleus (SCN) of the hypothalamus. The SCN is entrained by environmental factors, particularly light, to the 24-hour light-dark cycle by the Earth’s rotation. Peripheral circadian oscillators
-
Human Derived Dermal Fibroblasts as in Vitro Research Tool to Study Circadian Rhythmicity in Psychiatric Disorders Pharmacopsychiatry (IF 4.3) Pub Date : 2023-05-15 Denise Palm, Adriana Uzoni, Golo Kronenberg, Johannes Thome, Frank Faltraco
A number of psychiatric disorders are defined by persistent or recurrent sleep-wake disturbances alongside disruptions in circadian rhythm and altered clock gene expression. Circadian rhythms are present not only in the hypothalamic suprachiasmatic nucleus but also in peripheral tissues. In this respect, cultures of human derived dermal fibroblasts may serve as a promising new tool to investigate cellular
-
The Role of Mood Stabilizers in Children and Adolescents with Anorexia Nervosa: A 1-year Follow-Up, Propensity Score-Matched Study Pharmacopsychiatry (IF 4.3) Pub Date : 2023-05-15 Jacopo Pruccoli, Antonia Parmeggiani
Background The existing literature on the use of mood stabilizers (MS) in children and adolescents with anorexia nervosa (AN) is limited, for the most part, to small case studies. Methods This was an observational, naturalistic, propensity score-matched study. Subjects treated and not-treated with MS were compared by being matched via propensity score on age, sex, concurrent atypical antipsychotics
-
Effects of Anesthesia Changes During Maintenance ECT: A Longitudinal Comparison of Seizure Quality Under Anesthesia Using Propofol/Esketamine Versus Methohexital Pharmacopsychiatry (IF 4.3) Pub Date : 2023-04-28 Isabel Methfessel, David Zilles-Wegner, Nils Kunze-Szikszay, Michael Belz
Introduction The effectiveness of ECT relies on the induction of a generalized cerebral seizure. Among others, seizure quality (SQ) is potentially influenced by the anesthetic drug used. Commonly used anesthetics comprise barbiturates, etomidate, propofol, and esketamine, with different characteristics and impacts on seizure parameters. So far, no studies have compared the influence of methohexital
-
Low Escitalopram Concentrations in Patients with Depression predict Treatment Failure: A Naturalistic Retrospective Study Pharmacopsychiatry (IF 4.3) Pub Date : 2023-03-21 Xenia M. Hart, Friederike Amann, Jonas Brand, Luzie Eichentopf, Gerhard Gründer
Introduction Cross sectional therapeutic drug monitoring (TDM) data mining introduces new opportunities for the investigation of medication treatment effects to find optimal therapeutic windows. Medication discontinuation has been proven useful as an objective surrogate marker to assess treatment failure. This study aimed to investigate the treatment effects of escitalopram and pharmacokinetic influences
-
DNA Methylation of POMC and NR3C1-1F and Its Implication in Major Depressive Disorder and Electroconvulsive Therapy Pharmacopsychiatry (IF 4.3) Pub Date : 2023-03-21 Hannah B. Maier, Nicole Moschny, Franziska Eberle, Kirsten Jahn, Thorsten Folsche, Rasmus Schülke, Stefan Bleich, Helge Frieling, Alexandra Neyazi
Introduction Precision medicine in psychiatry is still in its infancy. To establish patient-tailored treatment, adequate indicators predicting treatment response are required. Electroconvulsive therapy (ECT) is considered one of the most effective options for pharmacoresistant major depressive disorder (MDD), yet remission rates were reported to be below 50%. Methods Since epigenetics of the stress
-
The Mini-TRH Test Pharmacopsychiatry (IF 4.3) Pub Date : 2022-12-09 Johan Spoov
Thyrotropin-releasing hormone (TRH), at doses lower than those needed to stimulate prolactin secretion directly, can almost completely antagonize dopamine inhibition of prolactin release. In normal men, prolactin increases 15 min following an i. v. bolus of 12.5 µg TRH (the mini-TRH test), but not the maximal prolactin response to TRH or basal prolactin, positively correlated with prolactin response
-
Dexmedetomidine in Psychiatry: Repurposing of its Fast-Acting Anxiolytic, Analgesic and Sleep Modulating Properties. Pharmacopsychiatry (IF 4.3) Pub Date : 2022-11-16 Oliver G Bosch,Dario A Dornbierer,Francesco Bavato,Boris B Quednow,Hans-Peter Landolt,Erich Seifritz
Drug repurposing is a strategy to identify new indications for already approved drugs. A recent successful example in psychiatry is ketamine, an anesthetic drug developed in the 1960s, now approved and clinically used as a fast-acting antidepressant. Here, we describe the potential of dexmedetomidine as a psychopharmacological repurposing candidate. This α2-adrenoceptor agonist is approved in the US
-
Serious Adverse Drug Reactions to Antipsychotics in Minors with Multiple Disabilities: Preventability and Potential Cost Savings by Therapeutic Drug Monitoring Pharmacopsychiatry (IF 4.3) Pub Date : 2022-11-04 Stefanie Fekete, Tim Güntzel, Karin Egberts, Julia Geissler, Antje Neubert, Manfred Gerlach, Marcel Romanos, Regina Taurines
Introduction Children and adolescents with multiple disabilities and mental disorders (CAMD) are frequently treated with antipsychotic drugs. However, CAMD are particularly susceptible to serious adverse drug reactions (sADRs). This retrospective study examined the frequency of sADRs to antipsychotics in CAMD. Further, the potential preventability of these sADRs through therapeutic drug monitoring
-
Antipsychotic Monotherapy for Major Depressive Disorder: A Systematic Review and Meta-Analysis Pharmacopsychiatry (IF 4.3) Pub Date : 2022-10-18 Akira Nishi, Kyosuke Sawada, Hiroyuki Uchida, Masaru Mimura, Hiroyoshi Takeuchi
Although several randomized controlled trials (RCTs) have compared the effectiveness, efficacy, and safety of antipsychotic monotherapy (APM) versus placebo in patients with major depressive disorder (MDD), no meta-analysis has examined this topic. We conducted a systematic literature search using MEDLINE and Embase to identify relevant RCTs and performed a meta-analysis to compare the following outcomes
-
Metformin is Protective Against the Development of Mood Disorders Pharmacopsychiatry (IF 4.3) Pub Date : 2022-09-28 Jacqueline Lake, Chiara C. Bortolasci, Amanda L. Stuart, Julie A. Pasco, Srisaiyini Kidnapillai, Briana Spolding, Trang T. T. Truong, Bruna Panizzutti, Zoe S. J. Liu, Olivia M. Dean, Tamsyn Crowley, Mark Richardson, Jee Hyun Kim, Michael Berk, Lana J. Williams, Ken Walder
Introduction Mood disorders are a major cause of disability, and current treatment options are inadequate for reducing the burden on a global scale. The aim of this project was to identify drugs suitable for repurposing to treat mood disorders. Methods This mixed-method study utilized gene expression signature technology and pharmacoepidemiology to investigate drugs that may be suitable for repurposing
-
Selective Serotonin Reuptake Inhibitors may Influence COVID-19 Prognosis through Antioxidant and Cytoprotective Pathways Mediated by Sigma 1 Receptor Agonism. Pharmacopsychiatry (IF 4.3) Pub Date : 2022-08-18 Konstantinos I Papadopoulos,Alexandra Papadopoulou,Tar-Choon Aw
-
Linkage of Young Mania Rating Scale to Clinical Global Impression Scale to Enhance Utility in Clinical Practice and Research Trials Pharmacopsychiatry (IF 4.3) Pub Date : 2022-07-27 Myrto T. Samara, Stephen Z. Levine, Stefan Leucht
Introduction The Young Mania Rating Scale (YMRS) is the gold standard to assess manic symptoms of bipolar disorder, yet the clinical meaning of scores is unknown. To clinically understand and interpret YMRS scores, we examined linkages between the total and change scores of YMRS with the Clinical Global Impression (CGI) ratings. Methods Individual participant data (N=2,988) from eight randomized, double-blind
-
Effects of Pharmacokinetic Gene Variation on Therapeutic Drug Levels and Antidepressant Treatment Response Pharmacopsychiatry (IF 4.3) Pub Date : 2022-07-15 Maike Scherf-Clavel, Heike Weber, Catherina Wurst, Saskia Stonawski, Leif Hommers, Stefan Unterecker, Christiane Wolf, Katharina Domschke, Nicolas Rost, Tanja Brückl, Susanne Lucae, Manfred Uhr, Elisabeth B. Binder, Andreas Menke, Jürgen Deckert
Introduction Pharmacogenetic testing is proposed to minimize adverse effects when considered in combination with pharmacological knowledge of the drug. As yet, limited studies in clinical settings have investigated the predictive value of pharmacokinetic (pk) gene variation on therapeutic drug levels as a probable mechanism of adverse effects, nor considered the combined effect of pk gene variation
-
The Therapeutic Potential of Pimavanserin in the Treatment of Hallucinogen Induced Psychosis and Persistent Perceptual Symptoms. Pharmacopsychiatry (IF 4.3) Pub Date : 2022-07-11 Mark A Colijn
-
Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) Study Pharmacopsychiatry (IF 4.3) Pub Date : 2022-07-06 Helena K. Kim, Gwyneth Zai, Daniel J. Müller, Muhammad I. Husain, Raymond W. Lam, Benicio N. Frey, Claudio N. Soares, Sagar V. Parikh, Roumen Milev, Jane A. Foster, Gustavo Turecki, Faranak Farzan, Benoit H. Mulsant, Sidney H. Kennedy, Shreejoy J. Tripathy, Stefan Kloiber
Introduction An increasing number of studies are examining the link between the endocannabinoidome and major depressive disorder (MDD). We conducted an exploratory analysis of this system to identify potential markers of treatment outcomes. Methods The dataset of the Canadian Biomarker Integration Network in Depression-1 study, consisting of 180 patients with MDD treated for eight weeks with escitalopram
-
Aripiprazole Once-Monthly Versus Oral Aripiprazole for Schizophrenia in the Maintenance Phase: A Systematic Review and Network Meta-Analysis Pharmacopsychiatry (IF 4.3) Pub Date : 2022-07-05 Taro Kishi, Kenji Sakuma, Nakao Iwata
IntroductionTo examine whether aripiprazole once-monthly (AOM) was more beneficial than oral aripiprazole (OARI) in the treatment of adults with schizophrenia during the maintenance phase. MethodsWe performed a systematic review and network meta-analysis of double-blind, randomized controlled trials that included two of the following treatments: AOM, OARI, and placebo. ResultsWe identified four studies
-
Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs Pharmacopsychiatry (IF 4.3) Pub Date : 2022-07-01 Javier-David Lopez-Morinigo, Stefan Leucht, Celso Arango
Early-onset schizophrenia (EOS) – onset before age 18 – is linked with great disease burden and disability. Decision-making for EOS pharmacological treatment may be challenging due to conflicting information from evidence and guidelines and unidentified care needs may remain unmet. We searched for systematic reviews, meta-analyses and umbrella reviews of EOS pharmacological treatment published in PubMed
-
Influence of NOS1AP Risk Variants on the Corrected QT (QTc) Interval in the Pharmacotherapy of Schizophrenia Pharmacopsychiatry (IF 4.3) Pub Date : 2022-06-22 Dilhan Esen-Sehir, Juliane Kopf, Sandra Hägele, Michael M. Plichta, Andreas Reif, Florian Freudenberg
Introduction The variants of the gene for nitric oxide synthase 1 adaptor protein (NOS1AP) are associated with schizophrenia and cardiovascular deficits involving corrected QT (QTc) interval prolongation. Here, we investigated a possible pharmacogenetic effect of antipsychotic treatment on QTc length in interaction with two NOS1AP variants (rs12143842 and rs10494366) whose minor alleles are associated
-
COVID-19 Prognosis in Association with Antidepressant Use Pharmacopsychiatry (IF 4.3) Pub Date : 2022-06-02 Kyung Hyun Min, Tae Hyeok Kim, Soo Jin Oh, Woorim Kim, Kyung Eun Lee
Introduction Various subtypes of severe acute respiratory syndrome coronavirus 2 and variations among immune systems in different ethnicities need to be considered to understand the outcomes of coronavirus disease 2019 (COVID-19). This study aimed to provide evidence for the association between the use of antidepressants and the severity of COVID-19. Methods We used the National Health Information
-
Clinical Outcomes after Clozapine Discontinuation in Patients with Schizophrenia: A Systematic Review Pharmacopsychiatry (IF 4.3) Pub Date : 2022-05-05
Introduction Clozapine is the gold standard of treatment for patients with treatment-resistant schizophrenia. However, approximately 60% of those patients do not respond to clozapine; moreover, clinical outcomes after clozapine discontinuation are unclear so far. Therefore, we conducted a systematic review to clarify the outcomes after clozapine discontinuation. Methods A systematic literature search
-
Epigenetics for Drug Discovery: Dissecting the Effect of High Antipsychotic Dosage and D2 Blockage on Peripheral DNA Methylation Pharmacopsychiatry (IF 4.3) Pub Date : 2022-04-28 Christopher Adanty, Julia Kim, John Strauss, Jessica Qian, Gary Remington, Carol Borlido, Ariel Graff, Philip Gerretsen, Vincenzo De Luca
Introduction The relationship between genetic polymorphisms of antipsychotic drug-metabolizing agents and drug receptors has been often investigated. DNA methylation is a form of epigenetic modification that regulates gene expression. Few studies have analyzed the relationship between genome-wide methylation patterns and antipsychotic dosage. The primary aim of this pilot study was to investigate the
-
Factors Associated with Medication Adherence to Long-Acting Injectable Antipsychotics: Results from the STAR Network Depot Study Pharmacopsychiatry (IF 4.3) Pub Date : 2022-04-25
Introduction Long-acting injectable (LAI) antipsychotics are prescribed to people with severe psychiatric disorders who show poor adherence to oral medication. The present paper examined factors potentially associated with medication adherence to LAI treatment. Methods The STAR (Servizi Territoriali Associati per la Ricerca) Network Depot Study was a multicenter, observational, prospective study that
-
Morphological Representation of C1q in the Aging Central Nervous System Pharmacopsychiatry (IF 4.3) Pub Date : 2022-03-16 Christian Rupprecht, Rim S. J. Sarker, Gerhard Rammes
Introduction The complement protein C1q is essential for the innate immune system and neurophysiological and neuropathological processes. To gain more insight into these functions in the CNS, a comprehensive understanding of the morphological representation, especially of its cellular and subcellular target structures, is of great importance. Methods For a free-floating preparation, the brains of wild-type
-
Drug Combinations for Mood Disorders and Physical Comorbidities That Need Attention: A Cross-Sectional National Database Survey Pharmacopsychiatry (IF 4.3) Pub Date : 2022-02-04 Shin Kuramochi, Taisuke Yatomi, Takahito Uchida, Hiroyoshi Takeuchi, Masaru Mimura, Hiroyuki Uchida
Introduction This study investigated combined prescriptions of drugs for mood disorders and physical comorbidities that need special attention in the light of frequent physical comorbidities in patients with mood disorders. Methods We used the claims sampling data of 581,990 outpatients in January 2015 from the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Fisher’s
-
Serious Adverse Drug Reactions in Children and Adolescents Treated On- and Off-Label with Antidepressants and Antipsychotics in Clinical Practice Pharmacopsychiatry (IF 4.3) Pub Date : 2022-02-07 Karin M. Egberts, Manfred Gerlach, Christoph U. Correll, Paul L. Plener, Uwe Malzahn, Peter Heuschmann, Stefan Unterecker, Maike Scherf-Clavel, Hans Rock, Gisela Antony, Wolfgang Briegel, Christian Fleischhaker, Alexander Häge, Tobias Hellenschmidt, Harmut Imgart, Michael Kaess, Andreas Karwautz, Michael Kölch, Karl Reitzle, Tobias Renner, Su-Yin Reuter-Dang, Christian Rexroth, Gerd Schulte-Körne,
Introduction Despite the growing evidence base for psychotropic drug treatment in pediatric patients, knowledge about the benefit-risk ratio in clinical practice remains limited. The ‘Therapeutic Drug Monitoring (TDM)-VIGIL’ study aimed to evaluate serious adverse drug reactions (ADRs) in children and adolescents treated with antidepressants and/or antipsychotics in approved (‘on-label’), and off-label
-
Classic Psychedelic Drugs: Update on Biological Mechanisms Pharmacopsychiatry (IF 4.3) Pub Date : 2022-01-25 Vollenweider, Franz X., Smallridge, John W.
Renewed interest in the effects of psychedelics in the treatment of psychiatric disorders warrants a better understanding of the neurobiological mechanisms underlying the effects of these substances. During the past two decades, state-of-the-art studies of animals and humans have yielded new important insights into the molecular, cellular, and systems-level actions of psychedelic drugs. These efforts
-
Neuropsychiatric Drugs Against COVID-19: What is the Clinical Evidence? Pharmacopsychiatry (IF 4.3) Pub Date : 2022-01-25 Mueller, Juliane K., Riederer, Peter, Müller, Walter E.
Since the beginning of the coronavirus disease (COVID)-19 pandemic, the need for effective treatments for COVID-19 led to the idea of “repurposing” drugs for antiviral treatment. Several antipsychotics and antidepressants have been tested for in vitro activity against the severe acute respiratory syndrome coronavirus 2. Chlorpromazine, other phenothiazine antipsychotics, and the antidepressant fluoxetine
-
Covid-19: Contributions from Psychopharmacology Pharmacopsychiatry (IF 4.3) Pub Date : 2022-01-25 Bauer, Michael, Juckel, Georg
The COVID-19 pandemic is causing a major burden on personal health, healthcare systems and the global economy. For the last two years the COVID-19 pandemic has dramatically changed our lives in many personal and professional areas. For millions of us, due to infection rates, but also to protection measures such as lockdowns the corona pandemic has significantly changed the way we work, how we live